NCT04132817View on ClinicalTrials.gov

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

August 15, 2022

Study Completion Date

August 15, 2022

Conditions
Breast Cancer
Interventions
BIOLOGICAL

Nivolumab

specified dose on specified days

BIOLOGICAL

Ipilimumab

specified dose on specified days

DRUG

Nab-paclitaxel

specified dose on specified days

Trial Locations (8)

10016

Local Institution - 0008, New York

15213

Local Institution, Pittsburgh

63110

Local Institution - 0002, St Louis

75390

Local Institution, Dallas

78229

South Texas Accelerated Research Therapeutics, San Antonio

80045

Local Institution - 0009, Aurora

90033

Local Institution, Los Angeles

95817

Local Institution - 0003, Sacramento

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY